Home » Stocks » AXGN

Axogen, Inc. (AXGN)

Stock Price: $17.18 USD -1.17 (-6.38%)
Updated Jan 27, 2021 4:00 PM EST - Market closed
After-hours: $17.20 +0.02 (0.12%) Jan 27, 5:25 PM
Market Cap 697.83M
Revenue (ttm) 107.97M
Net Income (ttm) -24.81M
Shares Out 40.09M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $17.18
Previous Close $18.35
Change ($) -1.17
Change (%) -6.38%
Day's Open 17.92
Day's Range 17.07 - 18.23
Day's Volume 363,190
52-Week Range 7.35 - 20.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 2 weeks ago

The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price o...

Other stocks mentioned: MATX, WK
GlobeNewsWire - 3 weeks ago

Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platfor...

GlobeNewsWire - 1 month ago

ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral ...

Seeking Alpha - 1 month ago

AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement

GlobeNewsWire - 2 months ago

ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral ...

Seeking Alpha - 2 months ago

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today rep...

GlobeNewsWire - 3 months ago

ALACHUA, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral ...

Seeking Alpha - 3 months ago

COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.

GlobeNewsWire - 3 months ago

Healthcare veteran brings 30+ years of medtech experience to Axo g en, Inc. Board of Directors

GlobeNewsWire - 4 months ago

ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periph...

GlobeNewsWire - 4 months ago

New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft New data highlights the clinical and economic value of Avance® Nerve Graft compared to ne...

GlobeNewsWire - 4 months ago

ALACHUA, Fla., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periphe...

Seeking Alpha - 5 months ago

AxoGen's (AXGN) CEO Karen Zaderej on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 5 months ago

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periphe...

GlobeNewsWire - 6 months ago

RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company’s Biologics License Application (B...

GlobeNewsWire - 6 months ago

ALACHUA, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to periphera...

GlobeNewsWire - 6 months ago

ALACHUA, Fla., July 01, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...

GlobeNewsWire - 7 months ago

Freitag will continue as member of board of directors and serve as special counsel in transitional role through October Freitag will continue as member of board of directors and serve as speci...

GlobeNewsWire - 8 months ago

ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripher...

Seeking Alpha - 8 months ago

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

ALACHUA, Fla., April 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today ...

GlobeNewsWire - 10 months ago

ALACHUA, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periph...

Seeking Alpha - 11 months ago

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Largest peripheral nerve repair registry in the world generates clinical evidence of repair, safety, and outcomes data for peripheral nerve injuries Largest peripheral nerve repair registry in...

Seeking Alpha - 1 year ago

AxoGen Working Its Way Out Of The Penalty Box, But Execution Is Key

GlobeNewsWire - 1 year ago

Company will develop an automated bioprocessing system for human tissue scaffolds

GlobeNewsWire - 1 year ago

Parade float will highlight the life-changing power of tissue and organ donation Parade float will highlight the life-changing power of tissue and organ donation

Seeking Alpha - 1 year ago

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

ALACHUA, Fla., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periph...

GlobeNewsWire - 1 year ago

Updated outcomes data from the RANGER ® Registry’s  MATCH SM cohort will be presented during scientific sessions

GuruFocus - 1 year ago

Insiders invest in Capri Holdings, General Electric, Sarepta Therapeutics, Ryman Hospitality Properties and Axogen.

Other stocks mentioned: CPRI, GE, RHP, SRPT
GuruFocus - 1 year ago

CEO of Axogen Inc (30-Year Financial, Insider Trades) Karen L. Zaderej (insider trades) bought 75,000 shares of AXGN on 08/09/2019 at an average price of $13.5 a share.

Seeking Alpha - 1 year ago

AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Amidst worries about market size, competition, trial design, and executive turnover, AxoGen has also suffered from a rotation away from growth med-tech that had propelled sector multiples to l...

GuruFocus - 1 year ago

Axogen, Evolent Health present appealing opportunities.

Other stocks mentioned: EVH
Seeking Alpha - 1 year ago

AxoGen's (AXGN) CEO Karen Zaderej on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About AXGN

AxoGen, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is u... [Read more...]

Industry
Medical Devices
CEO
Karen Zaderej
Employees
371
Stock Exchange
NASDAQ
Ticker Symbol
AXGN
Full Company Profile

Financial Performance

In 2019, Axogen's revenue was $106.71 million, an increase of 27.13% compared to the previous year's $83.94 million. Losses were -$29.14 million, 30.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Axogen stock is "Buy." The 12-month stock price forecast is 21.33, which is an increase of 24.16% from the latest price.

Price Target
$21.33
(24.16% upside)
Analyst Consensus: Buy